ENOV News and Press, Enovis Corporation From 03/15/23

2023-03-15 16:39:47 ET Medical technology company Enovis ( NYSE: ENOV ) appointed CEO Matt Trerotola to the additional position of board chair, effective following the May 16 annual meeting of stockholders. Current Chair Mitchell Rales will retire on the same day...

Wilmington, March 15, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that CEO Matt Trerotola will assume the additional position of Chair of the Board, effective following the Company’s 2023 Annual ...

Wilmington, DE, March 03, 2023 (GLOBE NEWSWIRE) -- Enovis Corporation (NYSE: ENOV), an innovation-driven medical technology company, announced that it will feature its next generation of medical technology at the upcoming American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting Marc...

Wilmington, DE, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Today, Enovis Corporation (NYSE: ENOV), an innovation-driven medical technology company, announced that it has been recognized as one of America’s Greatest Workplaces for Diversity by Newsweek . The listing recognizes the best workplace...

Summary Enovis came up a little short with revenue and margins for both the fourth quarter of 2022 and guidance for 2023. The Reconstructive segment is performing well, with growth in U.S. hips, knees, and extremities that was well ahead of the group. The Prevention & Recovery b...

Enovis Corp (ENOV) Q4 2022 Earnings Conference Call February 23, 2023, 08:30 ET Company Participants Derek Leckow - VP, IR Matthew Trerotola - CEO & Director Phillip Berry - CFO Conference Call Participants Vikramjeet Chopra - Wells Fargo Securities ...

Shares of Enovis ( NYSE: ENOV ) on Thursday fell as much as 11.9% to $54.27 after the company reported mixed Q4 results and provided disappointing FY 2023 adj. earnings guidance. ENOV earlier in the day posted Q4 adj. EPS of $0.72 which beat estimates by $0.06 . Revenue gr...

Enovis Corporation press release ( NYSE: ENOV ): Q4 Non-GAAP EPS of $0.72 beats by $0.06 . Revenue of $408.7M (+2.4% Y/Y) misses by $7.09M . Enovis’ fourth quarter net sales of $409 million grew 2% from the prior year, reflecting 5% organic growth offset by a 3%...

Wilmington, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2022. The Company will host an investor conference call a...

Enovis Corporation ( NYSE: ENOV ) is scheduled to announce Q4 earnings results on Thursday, February 23rd, before market open. The consensus EPS Estimate is $0.66 (+11.9% Y/Y) and the consensus Revenue Estimate is $415.79M. Over the last 2 years, ENOV has beaten EPS estimate...